Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
McMaster University
$2,937,119.00
Anti-Coronavirus Therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform
FY 2020-21
Summary
COVID-19 has been diagnosed in millions of persons and has caused several hundred thousand deaths. Effective treatments are urgently required.
We have created the "Anti-Coronavirus Therapies (ACT) to prevent COVID-19 disease progression" trials platform to rapidly evaluate whether several commonly available interventions can be repurposed for the treatment of COVID-19 disease. The specific aims of our research are to determine whether treatments that: (a) reduce the levels of virus in the body, (b) reduce the response by the body to the infection (i.e., inflammation), and (c) prevent blood clotting can prevent COVID-19 disease progression. We will test these treatments alone and in combination in two trials: (1) Outpatient trial: here we are trying to patients diagnosed with COVID-19 from needing to go to hospital. (2) Inpatient trial: here we are trying to prevent patients with COVID-19 who are already hospitalized from being admitted to the intensive care unit and from dying.
The trial started in Canada on April 21 and will eventually include about 4,000 patients from at least 100 centres and at least 12 countries around the world.
Department
Program
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429561
Name
Eikelboom John W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
COVID-19 Rapid Research - Therapeutics
Projecttitle
Anti-Coronavirus Therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$2,937,119
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Keyworddelim
Aspirin; Azithromycin; Chloroquine; Colchicine; Covid-19; Hospitalization; Hydroxychloroquine; Mortality; Randomized Trials; Rivaroxaban
Abstract
COVID-19 has been diagnosed in millions of persons and has caused several hundred thousand deaths. Effective treatments are urgently required.
We have created the "Anti-Coronavirus Therapies (ACT) to prevent COVID-19 disease progression" trials platform to rapidly evaluate whether several commonly available interventions can be repurposed for the treatment of COVID-19 disease. The specific aims of our research are to determine whether treatments that: (a) reduce the levels of virus in the body, (b) reduce the response by the body to the infection (i.e., inflammation), and (c) prevent blood clotting can prevent COVID-19 disease progression. We will test these treatments alone and in combination in two trials: (1) Outpatient trial: here we are trying to patients diagnosed with COVID-19 from needing to go to hospital. (2) Inpatient trial: here we are trying to prevent patients with COVID-19 who are already hospitalized from being admitted to the intensive care unit and from dying.
The trial started in Canada on April 21 and will eventually include about 4,000 patients from at least 100 centres and at least 12 countries around the world.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Eikelboom, John W; Anand, Sonia S; Avezum, Alvaro; Bangdiwala, Shrikant I; Belley-Côté, Emilie Prudence; Chan, Noel; Choudhri, Shurjeel; Dans, Antonio L; Diaz, Rafael; Farkouh, Michael E; Felix, Camilo; Gerstein, Hertzel C; Healey, Jeff S; Jolly, Sanjit S; Leong, Darryl; Loeb, Mark B; Lopéz, Jose P; Paré, Guillaume; Whitlock, Richard; Yusuf, Salim
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $2,937,119~ $0~